Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial
We thank C Jourdan and A Vogel for excellent technical assistance. This work was supported by the LOEWE Center for Cell and Gene Therapy Frankfurt, Hessisches Ministerium für Wissenschaft und Kunst (III L 4518/17.004 (2014)), the EUTOS funding program and the Deutsche José Carreras Leukämie Stiftung (to OGO and MAR). FL receives support from the Frankfurter Förderung ‘Nachwuchswissenschaftler’ of the Goethe University. BW was supported by Deutsche Krebshilfe.